Nour Shublaq, Clare Sansom and Peter V. Coveney Patient-Specific Modelling in Drug Design, Development and Selection Including its Role in Clinical Decision-Making Chemical Biology & Drug Design 81
Article first published online: 17 DEC 2012 | DOI: 10.1111/j.1747-0285.2012.01444.x
We describe how the advent of gene sequencing and omics technologies is set to transform the pharmaceutical industry. The days of the one-size-fits-all blockbuster drug are drawing to a close, as targetted drug selection adumbrates an era when increasingly personalised medicines are developed and administered, based on our ability to model the differential binding affinities of inhibitors to patient-specific protein sequences. Two clinical case studies are presented: cancer and HIV.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf